Research programme: viral infection therapeutics - GPC Biotech
Latest Information Update: 25 Sep 2019
Price :
$50 *
At a glance
- Originator Evotec AG; GPC Biotech AG
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Viral infections
Most Recent Events
- 16 May 2005 Hepatitis C programme is available for licensing (http://www.gpc-biotech.com)
- 02 Mar 2005 Axxima Pharmaceuticals has been acquired and merged into GPC Biotech AG
- 25 Jul 2003 The hepatitis B programme is available for licensing http://www.axxima.com